Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glycine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.83 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.83 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.83 |
| ▸ | GABRR1 | P24046 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.42 |
| ▸ | THRB | P10828 | 3/20 | 0.42 |
| ▸ | BLM | P54132 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.42 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.42 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycine SCHEMBL22949 | 0.96 | — | — | |
| Glycine SCHEMBL219254 | 0.96 | — | — | |
| Glycine SCHEMBL4274286 | 0.96 | GLRA1 (0.91) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL5712832 | 0.96 | — | — | |
| Glycine SCHEMBL8608021 | 0.96 | GLRA1 (0.91) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL2150066 | 0.92 | — | — | |
| Glycine SCHEMBL9474283 | 0.92 | GLRA1 (0.83) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL29168877 | 0.92 | — | — | |
| Glycine SCHEMBL2586660 | 0.92 | GLRA1 (0.83) | GLRA1SLC6A9OR51E2GABRR1LMNA | |
| Glycine SCHEMBL28665130 | 0.92 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 61 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4496874-A1 | A SOLID HARD SURFACE CLEANING COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-01-29 | — | — | EP | claimed |
| CN-118974224-A | Solid hard surface cleaning compositions | 联合利华知识产权控股有限公司 | 2024-11-15 | — | — | CN | claimed |
| WO-2023180053-A1 | A SOLID HARD SURFACE CLEANING COMPOSITION | UNILEVER IP HOLDINGS B.V. (NL) | 2023-09-28 | — | — | WO | claimed |
| CN-111803442-B | Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof | 广州一品红制药有限公司 | 2022-06-14 | — | — | CN | claimed |
| CN-111803442-A | Stabilizer for improving bioavailability of ammonium glycyrrhetate S liquid dosage form and application thereof | 广州一品红制药有限公司 | 2020-10-23 | — | — | CN | claimed |
| US-6077536-A | AMOXYCILLIN HYDRATE AND EFFERVESCENT ACID AND BASE COUPLE | BEECHAM GROUP PLC (GB) | 2000-06-20 | — | — | US | claimed |
| US-6051254-A | AMOXYCILLIN HYDRATE, AN EFFERVESCENT COUPLE, BETA.-LACTAMASE INHIBITOR; THE EFFERVESCENT COUPLE COMPRISES AN ACID COMPONENT AND AN ALKALINE COMPONENT | SMITHKLINE BEECHAM PLC (GB) | 2000-04-18 | — | — | US | claimed |
| US-20260085254-A1 | LAUNDRY COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2026-03-26 | — | — | US | disclosed |
| US-20260085255-A1 | LAUNDRY COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4663737-A1 | LAUNDRY UNIT DOSE PRODUCT | Unilever IP Holdings B.V. (NL) | 2025-12-17 | — | — | EP | disclosed |
| EP-4663738-A1 | LAUNDRY UNIT DOSE PRODUCT | Unilever IP Holdings B.V. (NL) | 2025-12-17 | — | — | EP | disclosed |
| EP-4658745-A1 | LAUNDRY COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-12-10 | — | — | EP | disclosed |
| EP-4584354-A1 | LAUNDRY COMPOSITION | Unilever IP Holdings B.V. (NL) | 2025-07-16 | — | — | EP | disclosed |
| US-20160220481-A1 | Low-Sodium Effervescent Pharmaceutical Formulations | EFFRX PHARMACEUTICALS SA (CH) | 2016-08-04 | — | — | US | disclosed |
| EP-3046549-A1 | LOW-SODIUM EFFERVESCENT PHARMACEUTICAL FORMULATIONS | Effrx Pharmaceuticals SA (CH) | 2016-07-27 | — | — | EP | disclosed |
| WO-2015040460-A1 | LOW-SODIUM EFFERVESCENT PHARMACEUTICAL FORMULATIONS | EFFRX PHARMACEUTICALS SA (CH) | 2015-03-26 | — | — | WO | disclosed |
| EP-1931222-B1 | GELLING COMPOSITIONS AND METHODS | FMC BIOPOLYMER AS (NO) | 2012-02-15 | — | — | EP | disclosed |
| EP-1931222-A2 | GELLING COMPOSITIONS AND METHODS | FMC Biopolymer AS (NO) | 2008-06-18 | — | — | EP | disclosed |
| US-20070087038-A1 | GELLING COMPOSITIONS AND METHODS | FMC BIOPOLYMER AS (NO) | 2007-04-19 | — | — | US | disclosed |
| WO-2007039294-A2 | GELLING COMPOSITIONS AND METHODS | FMC BIOPOLYMER AS (NO) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260085255-A1 | LAUNDRY COMPOSITION | MGAM, GYS2, GALK1 | GLRA1 3842/4885SLC6A9 807/4885OR51E2 4699/4885 |
| US-20260085254-A1 | LAUNDRY COMPOSITION | MGAM, TREH, GALK1 | GLRA1 3148/4885SLC6A9 772/4885OR51E2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.